血尿酸水平與初診帕金森病輕度認(rèn)知功能障礙相關(guān)性研究
發(fā)布時(shí)間：2018-09-06 19:19
【摘要】：目的探究血尿酸(uric acid,UA)水平與初診帕金森病(Parkinson's disease,PD)患者輕度認(rèn)知功能障礙的相關(guān)性。方法1.選取于我院神經(jīng)科第一次就診并且未進(jìn)行任何抗PD治療的80名PD患者(43名男性和37名女性)作為此項(xiàng)研究的觀察組,以上患者行Hoehn-Yahr分級(jí)(H-Y分級(jí))≤3.0級(jí)并且無(wú)癡呆臨床表現(xiàn)。隨機(jī)選取同時(shí)期于我院體檢的70名個(gè)體(35名男性和35名女性)作為對(duì)照組。2.分別測(cè)定觀察組及對(duì)照組個(gè)體的清晨空腹血UA及肌酐(Serum creatinine,SCr)濃度。3.根據(jù)H-Y分級(jí)將觀察組患者分為PD早期組和PD中期組。其中,PD早期組患者46例,包括24名男性和22名女性;PD中期組患者34例,包括19名男性和15名女性。4.根據(jù)帕金森病輕度認(rèn)知功能障礙(mild cognitive impairment,PD-MCI)診斷標(biāo)準(zhǔn)將PD患者分為無(wú)認(rèn)知功能障礙組(no cognitive impairment,PD-NCI)及PD-MCI組。其中,PD-NCI組患者48例,包括26名男性和22名女性;PD-MCI組患者32例,包括17名男性和15名女性。5.所有統(tǒng)計(jì)分析使用SPSS版本17.0進(jìn)行。結(jié)果1.一般臨床資料的比較:觀察組與對(duì)照組個(gè)體的年齡、女性比例、教育年限、SCr、體重指數(shù)(body mass index,BMI)等數(shù)據(jù)相比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05);血UA、蒙特利爾認(rèn)知評(píng)估量表(Motreal cognitive assess ment,MoCA)(中文版)分值相比較,差異具有統(tǒng)計(jì)學(xué)意義(P0.05)。2.PD-MCI組、PD-NCI組及對(duì)照組個(gè)體的SCr濃度相比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05);PD-MCI組、PD-NCI組的血UA濃度均低于對(duì)照組,PD-MCI組血UA濃度低于PD-NCI組,以上差異均具有統(tǒng)計(jì)學(xué)意義(P0.05)。3.對(duì)于女性個(gè)體,PD-MCI組、PD-NCI組血UA濃度均低于對(duì)照組,PD-MCI組血UA濃度低于PD-NCI組,以上差異均具有統(tǒng)計(jì)學(xué)意義(P0.05);對(duì)于男性個(gè)體,PD-MCI組、PD-NCI組血UA濃度均低于對(duì)照組,PD-MCI組血UA濃度低于PD-NCI組,以上差異均具有統(tǒng)計(jì)學(xué)意義(P0.05);PD-MCI組、PD-NCI組、對(duì)照組各組之間男女個(gè)體的血UA濃度比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。4.針對(duì)PD-MCI組患者的研究:PD早期組、中期組MoCA分值均低于對(duì)照組,PD早期組MoCA分值高于PD中期組,差異均具有統(tǒng)計(jì)學(xué)意義(P0.05);PD早期組、中期組UA濃度均低于對(duì)照組,差異均具有統(tǒng)計(jì)學(xué)意義(P0.05);PD早期組、中期組的血UA濃度相比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。5.針對(duì)PD-NCI組患者的研究:PD早期組、中期組MoCA分值均低于對(duì)照組,PD早期組MoCA分值高于PD中期組,差異均具有統(tǒng)計(jì)學(xué)意義(P0.05);PD早期組、中期組UA濃度均低于對(duì)照組,差異均具有統(tǒng)計(jì)學(xué)意義(P0.05);PD早期組、中期組的血UA濃度相比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。6.血UA濃度與PD患者M(jìn)oCA量表中的命名能力具有正相關(guān)性,與其余認(rèn)知領(lǐng)域無(wú)明顯相關(guān)性。結(jié)論1.PD患者較健康個(gè)體的血UA水平降低,并且伴有輕度認(rèn)知功能障礙PD患者較認(rèn)知功能正常PD患者的血UA水平會(huì)進(jìn)一步降低,這一結(jié)論對(duì)男女患者均適用。2.對(duì)于非癡呆PD患者來(lái)說(shuō),PD中期患者較PD早期的認(rèn)知功能評(píng)分低,血UA水平較健康個(gè)體的低,但所處不同分期患者的血UA水平無(wú)明顯差異。3.血UA濃度與PD患者M(jìn)oCA量表中的命名能力具有正相關(guān)性,與其余認(rèn)知領(lǐng)域無(wú)明顯相關(guān)性。4.血UA濃度的降低可能是PD的發(fā)生及其認(rèn)知功能下降的機(jī)制之一。
[Abstract]:Objective To explore the relationship between serum uric acid (UA) and mild cognitive impairment in newly diagnosed Parkinson's disease (PD) patients. Methods 1. 80 PD patients (43 men and 37 women) who were first treated in our department of Neurology and had not received any anti-PD treatment were selected as the observation group of this study. The ehn-Yahr grading (H-Y grading) was less than 3.0 and no clinical manifestations of dementia were observed. Seventy individuals (35 males and 35 females) were randomly selected as control group. 2. The UA and serum creatinine (SCr) concentrations in the morning fasting blood of the observation group and the control group were measured. 3. Patients in the observation group were divided into PD groups according to H-Y grading. There were 46 patients in the early PD group, including 24 males and 22 females; 34 patients in the middle PD group, including 19 males and 15 females. 4. According to the diagnostic criteria of mild cognitive impairment (PD-MCI), PD patients were divided into the non-cognitive impairment group (PD-MCI). Among them, 48 patients in the PD-NCI group, including 26 males and 22 females, 32 patients in the PD-MCI group, including 17 males and 15 females. Mass index, BMI and other data, there was no significant difference (P 0.05); blood UA, Montreal Cognitive Assessment (MoCA) (Chinese version) score, the difference was statistically significant (P 0.05). 2. PD-MCI group, PD-NCI group and the control group of individual SCR concentration, there was no significant difference (P 0.05); The serum UA concentration of PD-MCI group was lower than that of PD-NCI group. The above differences were statistically significant (P 0.05). 3. For female individuals, PD-MCI group and PD-NCI group, the serum UA concentration of PD-MCI group was lower than that of control group, and the serum UA concentration of PD-MCI group was lower than that of PD-NCI group, the above differences were statistically significant (P 0.05). The concentration of UA in CI group, PD-NCI group was lower than that in control group, and the concentration of UA in PD-MCI group was lower than that in PD-NCI group, the difference was statistically significant (P 0.05). There was no significant difference in the concentration of UA between male and female in PD-MCI group, PD-NCI group and control group (P 0.05). 4. Compared with the control group, the MoCA score of early PD group was higher than that of middle PD group, and the difference was statistically significant (P 0.05); UA concentration of early PD group and middle PD group was lower than that of the control group, the difference was statistically significant (P 0.05); UA concentration of early PD group and middle PD group was not statistically significant (P 0.05). The scores of MoCA in early PD group were significantly higher than those in middle PD group (P 0.05). The concentrations of UA in early PD group and middle PD group were significantly lower than those in control group (P 0.05). The concentrations of UA in early PD group and middle PD group were significantly lower than those in control group (P 0.05). Conclusion 1. The UA level of PD patients is lower than that of healthy individuals, and the UA level of PD patients with mild cognitive impairment is lower than that of PD patients with normal cognitive function. This conclusion is applicable to both male and female patients. For non-dementia PD patients, the cognitive function score in the middle stage of PD is lower than that in the early stage of PD, and the level of UA in blood is lower than that in healthy individuals, but there is no significant difference in the level of UA in different stages. 3. The concentration of UA in blood is positively correlated with the nomenclature ability of MoCA scale in PD patients, and has no significant correlation with other cognitive domains. It may be one of the mechanisms of the occurrence of PD and its cognitive decline.
【學(xué)位授予單位】：大連醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R742.5
本文編號(hào)：2227289
[Abstract]:Objective To explore the relationship between serum uric acid (UA) and mild cognitive impairment in newly diagnosed Parkinson's disease (PD) patients. Methods 1. 80 PD patients (43 men and 37 women) who were first treated in our department of Neurology and had not received any anti-PD treatment were selected as the observation group of this study. The ehn-Yahr grading (H-Y grading) was less than 3.0 and no clinical manifestations of dementia were observed. Seventy individuals (35 males and 35 females) were randomly selected as control group. 2. The UA and serum creatinine (SCr) concentrations in the morning fasting blood of the observation group and the control group were measured. 3. Patients in the observation group were divided into PD groups according to H-Y grading. There were 46 patients in the early PD group, including 24 males and 22 females; 34 patients in the middle PD group, including 19 males and 15 females. 4. According to the diagnostic criteria of mild cognitive impairment (PD-MCI), PD patients were divided into the non-cognitive impairment group (PD-MCI). Among them, 48 patients in the PD-NCI group, including 26 males and 22 females, 32 patients in the PD-MCI group, including 17 males and 15 females. Mass index, BMI and other data, there was no significant difference (P 0.05); blood UA, Montreal Cognitive Assessment (MoCA) (Chinese version) score, the difference was statistically significant (P 0.05). 2. PD-MCI group, PD-NCI group and the control group of individual SCR concentration, there was no significant difference (P 0.05); The serum UA concentration of PD-MCI group was lower than that of PD-NCI group. The above differences were statistically significant (P 0.05). 3. For female individuals, PD-MCI group and PD-NCI group, the serum UA concentration of PD-MCI group was lower than that of control group, and the serum UA concentration of PD-MCI group was lower than that of PD-NCI group, the above differences were statistically significant (P 0.05). The concentration of UA in CI group, PD-NCI group was lower than that in control group, and the concentration of UA in PD-MCI group was lower than that in PD-NCI group, the difference was statistically significant (P 0.05). There was no significant difference in the concentration of UA between male and female in PD-MCI group, PD-NCI group and control group (P 0.05). 4. Compared with the control group, the MoCA score of early PD group was higher than that of middle PD group, and the difference was statistically significant (P 0.05); UA concentration of early PD group and middle PD group was lower than that of the control group, the difference was statistically significant (P 0.05); UA concentration of early PD group and middle PD group was not statistically significant (P 0.05). The scores of MoCA in early PD group were significantly higher than those in middle PD group (P 0.05). The concentrations of UA in early PD group and middle PD group were significantly lower than those in control group (P 0.05). The concentrations of UA in early PD group and middle PD group were significantly lower than those in control group (P 0.05). Conclusion 1. The UA level of PD patients is lower than that of healthy individuals, and the UA level of PD patients with mild cognitive impairment is lower than that of PD patients with normal cognitive function. This conclusion is applicable to both male and female patients. For non-dementia PD patients, the cognitive function score in the middle stage of PD is lower than that in the early stage of PD, and the level of UA in blood is lower than that in healthy individuals, but there is no significant difference in the level of UA in different stages. 3. The concentration of UA in blood is positively correlated with the nomenclature ability of MoCA scale in PD patients, and has no significant correlation with other cognitive domains. It may be one of the mechanisms of the occurrence of PD and its cognitive decline.
【學(xué)位授予單位】：大連醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R742.5
【參考文獻(xiàn)】
相關(guān)期刊論文 前4條
1 何月;彭巧玲;周國(guó)慶;;帕金森病患者血尿酸水平與認(rèn)知功能的相關(guān)性研究[J];川北醫(yī)學(xué)院學(xué)報(bào);2016年02期
2 陳菊萍;姚建新;武燕;陳峗;毛成潔;劉春風(fēng);;特發(fā)性震顫與帕金森病的認(rèn)知障礙[J];中華醫(yī)學(xué)雜志;2014年31期
3 張玉虎;甘蓉;聶坤;王麗敏;趙潔皓;黃智恒;張雄;萬(wàn)鑫;王麗娟;;帕金森病認(rèn)知障礙與血尿酸水平的相關(guān)性分析[J];國(guó)際神經(jīng)病學(xué)神經(jīng)外科學(xué)雜志;2013年03期
4 王曉君;羅蔚鋒;王麗君;毛成潔;王蘭;劉春風(fēng);;帕金森病患者認(rèn)知功能與尿酸及相關(guān)因素分析[J];中華醫(yī)學(xué)雜志;2009年23期
，本文編號(hào)：2227289
本文鏈接：http://sikaile.net/yixuelunwen/shenjingyixue/2227289.html
最近更新
教材專著
